Mentions
Extended reach
Total likes
Video views
AI synopsis
Numerous mentions, such as the one stating that orforglipron 'significantly reduces body weight in obesity patients' and another describing it as a 'potential game-changer,' demonstrate a high level of interest and recognition of its impactful role. The tone and detailed discussion, including trial results of up to 11.2% weight loss over 72 weeks, reflect deep engagement, while the emphasis on FDA approval and market implications indicates a high potential impact on treatment paradigms.
Many mentions highlight the promising results and safety of orforglipron, indicating general agreement with the article's findings.
The mentions express strong curiosity about the drug's potential and market impact, reflecting high interest.
Participants delve into specific trial data, safety profiles, and implications, showing deep engagement with the research.
The widespread coverage, mention of regulatory approval, and implications for obesity treatment suggest that this development could significantly change clinical practice.
Scientists reveal pill that helps you lose 20% body weight. For years, powerful obesity medications have meant injections. But now, scientists say a daily pill may offer similar results – and greater access. Researchers have published results from a massive international trial of orforglipron, an oral drug that mimics GLP-1 hormones. The study followed more than 3,100 adults with obesity but not diabetes, across nine countries, for 72 weeks. Patients took either a placebo or one of three daily doses of orforglipron, alongside diet and activity. The results were striking. At the highest dose, patients lost an average of 11% of their body weight. More than half lost at least 10%, over one third lost 15% or more, and nearly one in five shed at least 20%. For comparison, the placebo group averaged just a 2% drop. Beyond weight, the pill improved waist size, blood pressure, triglycerides,
Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss www.nejm.org/doi/full/10....
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr #Endocrinology https://t.co/xFALCq2XqV
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/avDbBYKZDr
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/EdAknfDkki
Ya hay pastillas de GLP-1 aprobadas, y una de ellas te obliga a esperar treinta minutos. This new oral small-molecule GLP-1 receptor agonist, orforglipron, shows promising results in phase 3 trials for obesity…
Foundayo (orforglipron) is the first truly convenient GLP-1 weight loss pill — once daily, no food or water rules, and no injections. This video covers how it works, real results, side effects, dosing, cost, and…
Opieka dietetyczno-treningowa: mój program 'Metoda Szemraja' pomaga w osiągnięciu efektów. Nowy doustny lek na odchudzanie, orforglipron, wykazuje obiecujące wyniki w badaniach klinicznych. Dowiedz się, jak działa, jego…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, is showing promise in phase 3 trials for obesity treatment. Higher doses resulted in significant weight loss of up to 11.2%, with manageable mild to moderate…
Orforglipron, an oral GLP-1 receptor agonist, is being tested for weight loss in adults with obesity, showing promising results in a phase 3 trial over 72 weeks. Higher doses resulted in significant weight reduction…
2026 healthcare world is set to evolve with AI transforming into personal health coaches. New obesity treatments like oral GLP-1 receptor agonists show promising results, while cancer vaccines are making significant…
GLP-1 is a hormone your body naturally produces. This video explains what GLP-1 is, how exercise and diet can boost its levels, and its role in weight loss, helping you optimize your health without medication.
The FDA has approved the first true oral GLP-1 receptor agonist, forglipron, marketed as Foundayo. This video explains how it differs from Ozempic, how it survives stomach acid, and the real-world effectiveness based on…
Will the new once-daily Orforglipron pill disrupt the GLP-1 weight loss market? This video covers its chemistry, trial data, and how it compares to injectables like Mounjaro and Wegovy, highlighting implications for…
Obesity is often misconceived as mere laziness, but the underlying causes are complex. This video explores the science behind body fat regulation, genetics, hormones, and the emerging role of oral medications like…
This video explores the effectiveness and safety of orforglipron, a new oral GLP-1 receptor agonist for obesity. Clinical trials show an average weight loss of 11.2%, but side effects like gastrointestinal issues are…
If you want 1:1 GLP-1 support in 2026, start by joining my waitlist here. Over 20 million people use GLP-1 medications, mostly injections. Tablets like Rybelsus and new options such as Orforglipron are emerging, with…
In this episode of the Docs Who Lift Podcast, Dr. Spencer Nadolsky and colleagues analyze new oral GLP-1 medications like semaglutide and orforglipron. They discuss efficacy, challenges in oral dosing, and potential…
PA Ledyi Ballesteros discusses approved obesity medications targeting GLP-1, including formulations and dosing. Highlights include promising phase 3 trial results of orforglipron, an oral GLP-1 receptor agonist showing…
Orforglipron, an oral GLP-1 receptor agonist, has shown promising results in phase 3 trials for weight loss in adults with obesity. Higher doses resulted in significant weight reductions, with mostly mild to moderate…
New weight loss pill or Mounjaro injection — which one is right for you? Dr Fadul compares Foundayo, the FDA-approved oral GLP-1 agonist, with Mounjaro, a highly effective injectable, highlighting cost, convenience, and…
Foundayo just changed everything about weight loss. No needles, fasting, or water restrictions—just one pill daily. In clinical trials, patients lost an average of 27 pounds, with many achieving over 10% body weight…
Is the new weight loss drug Foundayo right for you? Dr. Howard explains the clinical data behind FDA approval and what you need to know. This video emphasizes evidence-based information over marketing hype, helping you…
GLP-1 obesity drugs are peptide-based and destroy their structure in the stomach, making digestion a challenge. Orforglipron offers a different approach as a small-molecule, non-peptide drug that passes through the…
Orforglipron, an oral GLP-1 receptor agonist, is being tested for weight loss in adults with obesity, showing promising results in a phase 3 trial over 72 weeks. High doses led to significant weight reductions, with…
Emagrecer com uma caneta e depois manter o resultado com um comprimido: onde termina a expectativa e começa a evidência? Nesta masterclass, a Dra. Carol Cientista explora o orforglipron, uma molécula não peptídica oral…
Orforglipron, Eli Lilly’s new oral GLP-1 receptor agonist, could revolutionize metabolic disease management. This video explores its pharmacology, recent trial results, and its potential as a small-molecule alternative…
Ozempic. Wegovy. Mounjaro. Zepbound. They're everywhere — but almost nobody explains what they actually do at the level of the biology. In this episode, I explain how GLP-1 and dual GIP/GLP-1 medications work, their…
I know the news came out on April 1st, but this is not a prank. A new non-peptide GLP-1 tablet called Foundayo has been approved, offering an effective alternative to injections. It works without fasting, providing a…
¿Puede un GLP-1 oral lograr una pérdida de peso clínicamente relevante sin necesidad de inyecciones? En este video analizamos ATTAIN-1, un ensayo clínico fase 3 publicado en The New England Journal of Medicine, que…
This clinician-focused lecture reviews what is new and what is coming next in glucagon-like peptide-1 (GLP-1) based therapy. The discussion covers current approved and emerging indications, oral and injectable…
In the latest episode, we explore how wellness, health, and longevity are evolving in 2026. Technologies like neurotech, advanced fitness trackers, precise health monitoring devices, new diabetes medications, allergy…
Orforglipron, now FDA-approved as Foundayo, is a groundbreaking oral small-molecule GLP-1 receptor agonist for obesity treatment. This video details its mechanism, compares it to injectable GLP-1 drugs like semaglutide…
A bold trial in valvular heart disease and a cardiovascular prevention trial highlight the importance of humility in medical practice. Discussing new approaches to TAVI, CV risk management, and the impact of full…
In this video, I'll cover the approval of Foundayo (orforglipron) as a treatment for weight loss and some of the topline efficacy and safety data based on pivotal clinical studies, and then add my own thoughts on what…
This issue will review recent developments including Orforglipron's potential for weight loss in obesity, its efficacy over 72 weeks, safety profile, and implications for clinical practice as reported in NEJM.
What to expect from GLP-1 medications for weight loss is a complex discussion. Current studies on drugs like Semaglutide, Tirzepatide, and emerging oral options such as Orforglipron show promising results, but…
Obesity is a complex, metabolic, and hormonal disease, not a lack of willpower. Recent science highlights orforglipron, an oral GLP-1 receptor agonist, which has shown significant weight loss in clinical trials…
Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. This episode discusses rapid weight regain after stopping GLP1 receptor agonists, introduces orforglipron, a promising oral GLP1ra for obesity and…
Orforglipron, an oral GLP-1 receptor agonist, has demonstrated significant weight loss in a large phase 3 trial. Participants taking 36 mg lost an average of 11.2% of body weight over 72 weeks, offering a potential…
Orforglipron, an oral GLP-1 receptor agonist, has demonstrated significant weight loss in adults with obesity over 72 weeks. Higher doses resulted in an average 11.2% body weight reduction, with mostly mild side…
Orforglipron, an oral GLP-1 receptor agonist, is being tested for weight loss in adults with obesity, showing promising results in a phase 3 trial over 72 weeks. Patients on higher doses lost significant weight, but…
There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick discusses the differences in chemistry, dosing, efficacy, side effects, and patient suitability for Foundayo…
Full appraisal: https://youtu.be/ufr94GJgnOw ATTAIN-2 tested once-daily oral orforglipron, a non-peptide small-molecule GLP-1 receptor agonist, at three doses versus placebo over 72 weeks. At the highest dose of 36 mg…
Orforglipron, an oral GLP-1 receptor agonist, is being tested in phase 3 trials for adult obesity. This video reviews its usage, effectiveness, side effects, and how it compares to injectable options, based on recent…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, is showing promising results in phase 3 trials for weight loss in adults with obesity. Higher doses resulted in significant weight reductions, with manageable…
The big GLP-1 guide: Abnehmspritzen, Wirkungsweise, Studien, Nebenwirkungen und die Zukunft der Adipositastherapie! This video explores how drugs like Wegovy, Ozempic, and Mounjaro work, compares key compounds like…
New medication for weight loss is on the horizon. Orforglipron, a small-molecule GLP-1 receptor agonist similar to semaglutide, offers effective results without the need for fasting. It may revolutionize obesity…
No vídeo de hoje apresento e discuto um artigo científico recente sobre o Orforglipron, um agonista oral do receptor de GLP-1 que tem se destacado como uma nova alternativa para o tratamento da obesidade e do diabetes…
Based on the 2026 FDA labels and major trials, this video explains how GLP-1 medicines like Wegovy, Zepbound, and new developments such as orforglipron work for weight loss, especially in older adults, and discusses…
GLP-1 weight-loss drugs are peptides — chains of amino acids. Swallow one and stomach acid unfolds it while proteases chop it into fragments. It stops being a drug and becomes food. Orforglipron, a non-peptide small…
This video discusses the principles, effects, and safety of GLP-1 receptor agonists like Wegovy, including new oral options such as orforglipron. Focus on efficacy in older adults, muscle loss, side effects, and recent…
This video is for education only and isn't medical advice. Orforglipron, a prescription GLP-1 medication, was studied across menopausal statuses, showing similar weight loss results—12.8% to 14.4% in non-diabetic women…
? The GLP-1 in tablet form is now a reality with orforglipron, an oral, non-peptidic agonist developed for daily use. Phase 3 trials demonstrate significant weight loss of up to 12.4%. While not yet available in Brazil…
Oral GLP-1 drugs may quiet brain cravings in ways that go beyond simple appetite control. A mouse study found that some oral GLP-1 medicines reduce the reward value of highly palatable food by acting on deep brain…
Howie and Harlan discuss innovative developments in GLP-1 obesity drugs, including orforglipron's promising phase 3 trial results, and explore new digital tools for personalized heart health management through ALYKA…
Orforglipron, an oral GLP-1 receptor agonist, is showing promising weight loss results in phase 3 trials, with higher doses achieving significant body weight reduction. Mild to moderate side effects were reported…
20/32 ATTAIN-1 — Orforglipron (2025). Tras 72 semanas, la pérdida media de peso osciló entre el 7,5 % y el 11,2 %, según la dosis, frente al 2,1 % con placebo. Adultos con obesidad sin diabetes. ? https://t.co/8vI3RuEkMD
Sources: https://t.co/XPouU7jcwI https://t.co/camcwGuLMQ
Sources: https://t.co/XPouU7jKmg https://t.co/camcwGvjCo
@DrChavezDiaz No pues prefiero orfoglipron... https://t.co/oX9BPTqNu4 y me quiero las molestias del viaje al más allá... ?
飲むだけで11％痩せる新薬は安全なのか？【GLP-1の効果・副作用】 https://t.co/fD1ohpH1Ig via @YouTube
ATTAIN-1: Orforglipron para obesidad DOI: 10.1056/NEJMoa2511774 https://t.co/XKQMzc5j0v
【肥満治療：経口非ペプチドGLP-1受容体作動薬orforglipron】 タイトル：Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment（ATTAIN-1） ✅️【出典】 New England Journal of Medicine, 2025 ✅️【研究デザイン】 第3相・国際多施設共同・二重盲検・無作為化・プラセボ対照試験。 ✅️【対象】 糖尿病のない成人肥満患者3,127例。 ✅️【介入・比較】 健康的な食事と身体活動に加え、経口orforglipron 6mg、12mg、36mgまたはプラセボを1日1回、72週間投与。 ✅️【主要評価項目】 72週時点におけるベースラインからの体重変化率。 ✅️【主要結果】 平均体重変化率は6mg群−7.5％、12mg群−8.4％、36mg群−11.2％、プラセボ群−2.1％で、すべての用量がプラセボより有意に大きな減量と関連しました。36mg群では、体重が10％以上減少した患者54.6％、15％以上36.0％、20％以上18.4％で、プラセボ群ではそれぞれ12.9％、5.9％、2.8％でした。 腹囲、収縮期血圧、中性脂肪、非HDLコレステロールも改善しました。有害事象による中止はorforglipron群5.3～10.3％、プラセボ群2.7％で、主な有害事象は軽度～中等度の消化器症状でした。 ✅️【臨床的解釈】 注射を必要としない低分子のGLP-1（glucagon-like peptide-1：食欲や血糖調節に関与する消化管ホルモン）受容体作動薬でも、用量依存的な体重減少が得られる可能性が示されました。注射製剤を希望しない患者の選択肢になり得ます。 ただし、本試験は既存の注射型GLP-1製剤との直接比較ではありません。心血管イベントの抑制、減量の長期維持、投与終了後の体重変化もこの試験だけでは判断できません。 ✅️【限界】 糖尿病のない肥満患者を対象とした72週間の試験で、長期安全性や心血管転帰は評価されていませ
It has also shown consistent results relative to other similar drugs .. The American FDA has approved it in April of this year following several successful clinical trials. This article can help provide more info on the drug: https://t.co/1Uj6Pr2Rm2
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/F3EewHorca
Ozempic in a Pill. Here's the Catch. https://t.co/s7EJt3ClDE via @YouTube
The board, each number tied to that drug’s own trial dose (no mixing arms): Retatrutide: 28.3% mean weight loss at 80 weeks, 12mg (TRIUMPH-1, Phase 3, n=2,335 per https://t.co/iRktt1QRB4). https://t.co/25mCtaMDL3 Tirzepatide: 22.5% at 15mg (SURMOUNT-1, n=2,539). https://t.co/5Ww4tKE1ie CagriSema: 22.7% on-treatment estimand (20.4% intention-to-treat), REDEFINE-1, n=3,417, peer-reviewed in NEJM 2025. https://t.co/anoXRiL0Yg Eloralintide: ~20% over 48 weeks at the top dose (Phase 2, selective amylin, no GLP-1; nausea is dose-specific). Lancet 2025: https://t.co/cfKAnzfzzP Orforglipron: oral, 11.2% weight loss at 36mg over 72 weeks in obesity (ATTAIN-1, the first oral once-daily GLP-1 pill; treatment-regimen estimand, ITT). NEJM Sept 2025, DOI 10.1056/NEJMoa2511774. Survodutide (a two-hormone GLP-1/glucagon agonist, not on the board above but worth knowing): about 17% (SYNCHRONIZ
GLP-1 Medications: What’s New and What’s Next for Clinicians https://t.co/yfk89uLu7m via @YouTube #medicine
https://t.co/ama7yRMNGs
https://t.co/EMKsaFrLG8
https://t.co/2DHZCHwxKL
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. There is a lot of interest among patients about this drug. It makes you loose about 11% body weight and could be cheaper then some of the current medication https://t.co/lqLNildrw3
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/9LYvheUUbX
#foundayo #glp1 #orforglipron #elilly https://t.co/OQciSLnopa
https://t.co/SW0j7JZcBL
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/si9OEMXjcI
Eli Lilly plans to invest USD3 billion over the next decade to expand its supply chain capacity in China, the US drugmaker said today. The firm will set up a local production and supply network for tablets and capsules and build manufacturing capabilities for orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. @EliLillyandCo
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/pXyxXZZdDS - administered by oral route
HOT TOPIC OF THE WEEK Most viewed paper on BioFingertips: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. This is what healthcare professionals are reading right now. Read it on BioFingertips: https://t.co/w2fEjD0vKT #BioFingertips #HotTopicOfTheWeek #GLP1 #ObesityTreatment #HealthcareProfessionals
For today's journal club, Dr. K C discussed the ??? ??????? ??????? ?? ???????? article “Orforglipron, an Oral Small Molecule GLP 1 Receptor Agonist for Obesity Treatment.” https://t.co/Hz36cwmQee
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://t.co/Ghr7pWJYrt
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. www.evidencealerts.com/Social/Artic...
EvidenceAlerts | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. www.evidencealerts.com/Social/Artic...
2026'da sağlık teknolojilerinde neler değişecek dersiniz? Videonun tamamı YouTube kanalımızda. Gelin birlikte 2026'da sağlıkta neler değişecek göz atalım. https://t.co/vgpzJ9Ffao #saglik #saglikteknolojileri #sağlıkhaberleri https://t.co/ESBOAf2ZT8
“Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.” Publié ce jour dans @thelancet.com. #MedSky #EndoSky www.thelancet.com/journals/lan...
[Articles] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/nWjxMHw4HK
www.nejm.org/doi/full/10.... www.thelancet.com/journals/lan...
2026 sağlık dünyası nasıl olacak? Yapay zekâ kişisel sağlık koçuna mı dönüşüyor? Zayıflama iğneleri yerini haplara mı bırakacak? Obezite cerrahisi azalacak mı? Kanser aşıları gerçekten yakın mı? Longevity neden yükselişte? https://t.co/4KPS9kyDkk #saglik #saglikhaberleri https://t.co/iS0u3qlZ45
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/WBgZgB9CHR
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/U3MIokvSsH
Good news for folk with excess weight and type 2 diabetes - an oral alternative to injectable GLP-1 receptor agonists. Dose response r/ship in weight loss and majority of participants getting below HbA1c of 6.5%. www.sciencedirect.com/science/arti...
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/EdAknfDkki
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://t.co/mgXNdNFFqL
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/qeiVoRpYfR
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Orforglipron, a once-daily oral GLP-1 agonist, shows promise for obesity. Tested 6mg, 12mg, 36mg vs. placebo in a 72-week study. Outcomes look positive! PMID:40960239, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2511774 #Medsky #Pharmsky #RNA #ASHG #ESHG
Orforglipron, a once-daily oral GLP-1 agonist, shows promise for obesity. Tested 6mg, 12mg, 36mg vs. placebo in a 72-week study. Outcomes look positive! PMID:40960239, N Engl J Med 2025, @NEJM https://t.co/O1bZlcZb00 #AI #Pharma #BioMed #RNA #ASHG #ESHG
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind. Orforglipron, in people with diabetes and obesity shows significant weight loss. https://t.co/mgXNdNFFqL
RT @agingdoc1: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/BkWNPBcty8
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial "We aimed to evaluate orforglipron, an oral small-molecule
RT @alexanderperse: I wonder if patient census in hospitals will go down due to this. Absolutely insane https://t.co/l1Hh3Uw0UU
www.nejm.org/doi/full/10....
Orforglipron significantly reduces body weight in obesity patients, outperforming placebo and showing favorable safety profile over 72 weeks. by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med https://t.co/OMCh2O5F2z #MedX #MedResearch
Orforglipron significantly reduces body weight in obesity patients, outperforming placebo and showing favorable safety profile over 72 weeks. by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med #MedSky
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. This new drug is way more effective for dropping pounds, and the best part is it's just a pill you swallow! Read. https://t.co/ggGKN8l1YK
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
8/
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
8/
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/rDlejWVqyO
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr #Endocrinology https://t.co/xFALCq2XqV
Oral easy-to-take GLP-1 Agonists are going to transform the market even more than injectables making them broadly adoptable. Implications are immense: Fewer hospital admissions (11% lower for heart failure, 20-24% lower among patients with diabetes for stroke and MI) Less money spent on food and possibly alcohol (5-10% lower grocery spend per user) Lower rates of hypertension, diabetes, high lipids Decreased obesity surgery by 10-15% 12% reduction in all-cause mortality Lower rates of kidney disease patients needing dialysis Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/QIqgGBbUUU (I have no interest in any pharmaceutical company and this will actually decrease the number of patients we get in the ER; it will make life tougher to finance hospitals)
https://t.co/b41lTXfxD5
In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with #obesity, as compared with placebo. Full trial results and Research Summary: nej.md/4n1nSl2 #MedSky #EndoSky
RT @yumino_medical: 【DrゆみのWeekly Journal Scan】 ■非糖尿病肥満成人に対する経口GLP1RAの効果 from NEJM https://t.co/O3R8IU3XP3…
RT @yumino_medical: 【DrゆみのWeekly Journal Scan】 ■非糖尿病肥満成人に対する経口GLP1RAの効果 from NEJM https://t.co/O3R8IU3XP3…
【DrゆみのWeekly Journal Scan】 ■非糖尿病肥満成人に対する経口GLP1RAの効果 from NEJM https://t.co/O3R8IU3XP3
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/zHzwg0rJ3A
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/HrFHV5wO6Q
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” Publié ce jour dans le @nejm.org. #MedSky #EndoSky www.nejm.org/doi/full/10....
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Dos nuevos fármacos orales
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @agingdoc1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/GNhaj2cf7G this week in @NEJM
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
Orforglipron, Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Rx. mean change in body weight from baseline to week 72 was −7.5% with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron,& −11.2% with 36 mg of orforglipron,vs −2.1% with placebo https://t.co/lYOuJqpnO6
RT @agingdoc1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/ifTueKLWh7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/SyI4OEeiom
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/R3Ye5VVhAg
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
Orforglipron, Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM. 3127 patients. mean change in body weight from baseline to week 72 was −7.5%, −8.2 to −6.8 with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, https://t.co/lYOuJqpnO6
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/lqLNildrw3
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
RT @NEJM: Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agon…
Here are three Original Articles from September that made big news: 1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/avDbBYKZDr
New Results from the ATTAIN-1 Phase 3 Trial: An Oral Small Molecule GLP-1 Receptor Agonist for Obesity Treatment. Click here to read the full results: https://t.co/HPqVcoKZ5Y https://t.co/hA4IrxqD0v
現代のやせ薬ことマンジャロは週1回の注射薬なので、まだ患者さんに通院の手間がかかる。 イーライリリーが臨床研究中のオルフォルグリプロンは常温の経口薬なので、もっと爆発的な市場を作る期待大！ 薬価収載前に自由診療で出回りそう https://t.co/UiBaN4iGYN
Scientists reveal pill that helps you lose 20% body weight. For years, powerful obesity medications have meant injections. But now, scientists say a daily pill may offer similar results – and greater access. Researchers have published results from a massive international trial of orforglipron, an oral drug that mimics GLP-1 hormones. The study followed more than 3,100 adults with obesity but not diabetes, across nine countries, for 72 weeks. Patients took either a placebo or one of three daily doses of orforglipron, alongside diet and activity. The results were striking. At the highest dose, patients lost an average of 11% of their body weight. More than half lost at least 10%, over one third lost 15% or more, and nearly one in five shed at least 20%. For comparison, the placebo group averaged just a 2% drop. Beyond weight, the pill improved waist size, blood pressure, triglycerides,
Orforglipron significantly reduces body weight in adults with obesity, outperforming placebo, while maintaining a tolerable safety profile. by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med #MedSky
Orforglipron significantly reduces body weight in adults with obesity, outperforming placebo, while maintaining a tolerable safety profile. by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med https://t.co/OMCh2O5F2z #MedX #MedResearch
We are proud to celebrate Dr. @SeanWharton, a founding member of BPAO, for publishing two groundbreaking studies in the New England Journal of Medicine on obesity treatment.
A groundbreaking international trial has revealed an oral drug called orforglipron that’s changing the obesity game. Unlike current injectable therapies, this is a once daily pill and its results are stunning. #OralTherapy #WeightLossScience #ScienceIsGood https://t.co/kk7vSNA9Ki https://t.co/K4Fqo8ZOXs
がより身近なものとなる可能性があります。オルフォルグリプロンは、米国食品医薬品局 (FDA) や世界中の他の同様の機関によってまだ承認されていません。https://t.co/hlkwAu8Opb
RT @EvidentisHQ: ATTAIN-1: once-daily oral GLP-1 agonist orforglipron cut weight by up to 11.2% at 72 wks vs 2.1% placebo in adults w/ obes…
Orforglipron（経口小分子GLP‑1受容体作動薬）、肥満（糖尿病なし）成人を対象とした72週の第3相で、体重減少がプラセボより有意に大。 脂肪量 −13.8％ 除脂肪量（lean mass） −4.5％ 内臓脂肪 −19.0％ 体重減少の内訳は 脂肪減少73％：除脂肪減少27％。 https://t.co/3sdLNnZeEu
RT @EvidentisHQ: ATTAIN-1: once-daily oral GLP-1 agonist orforglipron cut weight by up to 11.2% at 72 wks vs 2.1% placebo in adults w/ obes…
RT @nasreenalfaris: Thrilled to share our latest publication in @NEJM ,the ATTAIN-1 trial, the first phase 3 study of oral orforglipron in…
RT @CristobMorales: La democratización y uso temprano de los GLP1 pudiese llegar con los NUEVOS GLP1 orales https://t.co/df6shoUnMf Oral S…
RT @SemergenGTDM: ¿Inicio de una nueva era en el tto de la obesidad? Orforglipron podría cambiar el acceso a terapias GLP1: ✔️Vía de adm o…
¿Inicio de una nueva era en el tto de la obesidad? Orforglipron podría cambiar el acceso a terapias GLP1: ✔️Vía de adm oral diaria ✔️Sin necesidad de conservación especial ✔️Mejorando la adherencia y biodisponibilidad ✔️Eficacia clínicamente relevante https://t.co/Hxofi8F6aK
RT @NutrioSci: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than plac…
RT @NutrioSci: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than plac…
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. #NEJM www.nejm.org/doi/full/10....
RT @NutrioSci: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than plac…
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. @NEJM https://t.co/L9C3AGaFH7 https://t.co/m0AL980VUt
RT @DanielJDrucker: Oral orforglipron over 72 weeks for #weightloss #obesity #EASD2025 https://t.co/wuHNF2Jich
RT @EvidentisHQ: ATTAIN-1: once-daily oral GLP-1 agonist orforglipron cut weight by up to 11.2% at 72 wks vs 2.1% placebo in adults w/ obes…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/zHzwg0rJ3A
RT @DrSamuelBHume: Here are the sources: 1. Oral obesity drugs: https://t.co/91u4a6BLRt, https://t.co/21Z8Gg2C1X 2. Aspirin after colore…
Here are the sources: 1. Oral obesity drugs: https://t.co/91u4a6BLRt, https://t.co/21Z8Gg2C1X 2. Aspirin after colorectal cancer surgery https://t.co/KrGnVtz4jz 3. Trikafta in cystic fibrosis https://t.co/zd1vgzbask 4. Apple watch detects hypertension https://t.co/MTHhO5oCfH
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #MedTwitter
Ph3 ATTAIN-1 published in the #NEJM: #Lilly's PO GLP-1 (36mg), #orforglipron, demonstrated meaningful WL (~12.4%) & #cardiometabolic improvements @ wk 72 https://t.co/92OpaclqaN https://t.co/5qjQHKEhCg
RT @nasreenalfaris: Thrilled to share our latest publication in @NEJM ,the ATTAIN-1 trial, the first phase 3 study of oral orforglipron in…
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss https://t.co/DwMDkvsXg7 @NEJM https://t.co…
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists https://t.co/LvCFmJhA1z
RT @tarou_ymd_: マンジャロ打ってる人に朗報。 飲めるGLP-1作動薬の結果が報告されました。経口の小分子GLP-1作動薬「オルフォグリプロン」は ☑72週間で体重−11%減 ☑血圧・脂質も改善 「注射じゃなくても効く」時代、始まるかもしれません https://…
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #science #publication #research #publications https://t.co/VK62hraqjm
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/rWSnCVEQRh
RT @CristobMorales: La democratización y uso temprano de los GLP1 pudiese llegar con los NUEVOS GLP1 orales https://t.co/df6shoUnMf Oral S…
RT @medpedshosp: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https:…
Congrats to @seanwharton for two big oral GLP-1 papers in NEJM this week! ATTAIN-1 https://t.co/JliXctfaz1 OASIS-4 https://t.co/jFAnC572B4
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/PK5E4J7YMg
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment www.nejm.org/doi/10.1056/... #hvhebron #endo
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/Fd2WEsNMxw #hvhebron #endo
マンジャロ打ってる人に朗報。 飲めるGLP-1作動薬の結果が報告されました。経口の小分子GLP-1作動薬「オルフォグリプロン」は ☑72週間で体重−11%減 ☑血圧・脂質も改善 「注射じゃなくても効く」時代、始まるかもしれません https://t.co/mSHasGCtTD
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.”” Publié ce jour dans le @nejm.org. #MedSky #EndoSky www.nejm.org/doi/full/10....
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
La democratización y uso temprano de los GLP1 pudiese llegar con los NUEVOS GLP1 orales https://t.co/aqxJPwS90c Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity AND https://t.co/ZsK10EeNkQ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment #EASD2025
RT @SANCYDnutricion: Orforglipron, un agonista oral del receptor GLP-1 de moléculas pequeñas para el tratamiento de la obesidad Orforglipr…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/KoQ1oUc8s4
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/U3MIokvSsH
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM https://t.co/5Hox1DZcLh
Orforglipron, un agonista oral del receptor GLP-1 de moléculas pequeñas para el tratamiento de la obesidad Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/3aXXSmFxgf
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/TCwn2bK6zX
ATTAIN-1: once-daily oral GLP-1 agonist orforglipron cut weight by up to 11.2% at 72 wks vs 2.1% placebo in adults w/ obesity, also improving BP & lipids. GI AEs mild–mod 1st oral small-molecule GLP-1 with robust efficacy—potential game-changer in obesity https://t.co/x5GVydB79E
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treat…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine?✅ https://t.co/isRidvOoab
νάτο και το χαπάκι! Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/7pi2joNvDu
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. @NEJM @CMichaelGibson @DrMarthaGulati @hvanspall @lamcardio @AndrewJSauer @dranulala @ankeetbhatt @BiykemB @Drroxmehran @JACCJournals @ACCinTouch https://t.co/5t36x0kt8E
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/qQ9Eu6YFZp #EASD2025
Oral orforglipron over 72 weeks for #weightloss #obesity #EASD2025 www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/kYh2db5YxS
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment https://t.co/6p24qpMKnz
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment: NEJM; 3127 patients; mean change in body weight from baseline to week 72 was −7.5% , −8.2 to −6.8) with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, −11.2% https://t.co/lYOuJqpnO6
Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....
Orforglipron, an oral small-molecule GLP-1 agonist, significantly lowered blood glucose compared with placebo in a phase III trial. Read more on MIMS Pharma
). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N. Engl. J. Med. 2025, 393, 1796–1806. [Google Scholar] [CrossRef] ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Available from https://www.nejm.org/doi/10.1056/NEJMoa2511774 [Accessed 10th ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2500969 · https://www.nejm.org/doi/full/10.1056/NEJMoa2511774. About Robard: Nationally recognized hospitals and ...
doi: 10.1056/NEJMoa2511774. Pubmed Abstract · CrossRef · Google Scholar; View reference in article. 32. WiviottS. D.RazI.BonacaM. P.MosenzonO.KatoE. T.CahnA.et ...
doi: 10.1056/NEJMoa2511774. Crossref · PubMed · Google Scholar. 3. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller ...
Drug pipeline for February 2026 · ATTAIN-1 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 · Press release: https://investor.lilly.com/node/53581/pdf ...
doi: 10.1056/NEJMoa2511774. Go to Citation. Crossref · PubMed · Google Scholar. 3. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment – NEJM 4. Dementia Risk in People With Type 1 Diabetes and Associated Risk ...
... 10.1056/NEJMoa2511774. Overweight and obesity affect more than 2.5 billion persons worldwide and increase the risk of multiple health complications. 1. Long ...
This article was published on September. 16, 2025, at NEJM.org. DOI: 10.1056/NEJMoa2511774. Copyright © 2025 Massachusetts Medical Society. BACKGROUND.
doi:10.1056/NEJMoa2511774 2. Wharton S et al. OASIS 4 (oral semaglutide 25 mg). NEJM 2025;393:1077–1087 3. Sanyal AJ et al. ESSENCE Part 1 (semaglutide for ...
doi: 10.1056/NEJMoa2511774 Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #controldepeso #DrMikeDiabetes.
org/10.1056/NEJMoa2511774 2. Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2026). Orforglipron for maintenance of body weight reduction: The double ...
nejm.org/doi/full/10.1056/NEJMoa2511774 2. https://www.nejm. org/doi/full/10.1056/NEJMoa2504650 3. https://www.nejm. org/doi/full/10.1056/NEJMcibr2510197 4.
org/doi/full/10.1056/NEJMoa2511774 ATTAIN-2 Trial — The Lancet https://www.thelancet. com/journals/lancet/article/PIIS0140-6736(25)02165 -8/abstract Meta ...
https://doi.org/10.1056/NEJMoa2511774 • Horn DB, et al. The Lancet. 2025 ... https://doi.org/10.1056/NEJMoa2505669 #Metabolife #Orforglipron #Obesidad # ...
ORFORGLIPRON: AN ORAL SMALL- MOLECULE GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT AUTHORS. LEARNING OBJECTIVES Obesity , classification, management ...
doi: 10.1056/NEJMoa2511774; Foundayo [prescribing information]. 4/2026. Eli ... doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PMID: 40353578. Jastreboff ...
15150 [747] doi:10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26) ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
... 10.1056/NEJMoa2511774. https://www.nejm.org/doi/10.1056/NEJMoa2511774?referrer=https%3A%2F%2Fwww.google.com%2F ⚠️ Este contenido tiene ...
doi:10.1056/NEJMoa2500969 4. ATTAIN-1. NEJM 2025. doi: 10.1056/NEJMoa2511774 5. COR-I. Lancet 2010. doi: 10.1016/S0140-6736(10)60888-4 6. SCALE, ...
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” https://www.nejm.org/doi/10.1056/NEJMoa2511774. Protein ...
https://doi.org/10.1056/NEJMoa2511774 • Horn DB, et al. The Lancet ... https://doi.org/10.1056/NEJMoa2505669 #Metabolife #Orforglipron #Obesidad # ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment." New England Journal of Medicine. 2025. NCT05869903 ...
... 10.1056/NEJMoa2511774 Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #controldepeso ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine, 393(18), 1796–1806 ...
Like. Recent posts. Nuris Arelis González ▻ Medicos. 46w · Public · La obesidad sigue siendo una de las crisis de salud pública más ...
... 10.1056/NEJMoa2511774 • Orforglipron in Early Type 2 Diabetes (ACHIEVE-1), NEJM, June 2025 — https://pubmed.ncbi.nlm.nih.gov/40544435/ • Eli ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
DOI: 10.1056/NEJMoa2511774 3. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
5. Recent posts. Nuris Arelis González ▻ Medicos. 45w · Public · La obesidad sigue siendo una de las crisis de salud pública más ...
... 10.1056/NEJMoa2511774 · Horn DB, et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet. 2025 ...
doi:10.1056/NEJMoa2511774. #Orforglipron #Glp1 #Obesidad ... https://doi.org/10.1056/NEJMoa2511774 2. Aronne, L. J., Horn, D. B. ...
doi:10.1056/NEJMoa2511774. @dra.lorena.lequi · #Obesidad #MedicinaMetabólica #Tirzepatida #Semaglutida #CagriSema Orforglipron MASH ...
... . 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PMID: 40960239. | Leonardo Sande | Facebook. Log in · Video.
... 10.1056/NEJMoa2511774 · Horn DB, et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet. 2025 ...
doi:10.1056/NEJMoa2511774 · Aronne LJ, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026; 32 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl. J. Med. 2025, 393(18), 1796–1806. [Google Scholar] ...
... uma doença biologicamente heterogênea. DOI: 10.1056/NEJMoa2511774 Dr. Filippo Pedrinola CRM 62253-SP | RQE 26961".
... 10.1056/NEJMoa2511774 ▫ 結合の構造: Kawai et al., PNAS 2020;117(47):29959-29967 ▫ この薬には甲状腺C細胞腫瘍のリスク（げっ歯類での所見） ...
doi:10.1056/NEJMoa2511774. @dra.lorena.lequi · #Obesidad #MedicinaMetabólica #Tirzepatida #Semaglutida #CagriSema Orforglipron MASH ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
... 10.1056/NEJMoa2301972 2. Retatrutida — resultados de fase 3 https ... https://www.nejm.org/doi/abs/10.1056/NEJMoa2511774 6. MariTide ...
By validating that orforglipron is a small molecule rather than a trad Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for …
doi: 10.1056/NEJMoa2511774; Foundayo [prescribing information]. 4/2026. Eli Lilly & Co. Indianapolis, IN. Accessed April 8, 2026 at https ...
DOI: 10.1056/NEJMoa2511774 ATTAIN-MAINTAIN phase 3b, Nature Medicine (May 2026) — weight-loss maintenance after switching from injectables.
ergence of orforglipron—an orforglipron an oral small molecule glp 1 receptor agonist for obesity treatment—marks a departure from traditional ...
Unlike traditional Orforglipron: An Oral Small-Molecule GLP-1 Receptor Agonist for therapies that mimic natural amino acid chains—which are ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 ...
... 10.1056/NEJMoa2511774). · Binding geometry from Kawai et al., PNAS 2020;117(47):29959-29967 (DOI 10.1073/pnas.2014879117). · This drug ...
... 10.1056/NEJMoa2511774) 72주 treatment-regimen estimand 기준입니다. · 결합 구조는 Kawai et al., PNAS 2020;117(47):29959-29967 (DOI 10.1073 ...
... 10.1056/NEJMoa2511774 ATTAIN-MAINTAIN — Nature Medicine https://pubmed.ncbi.nlm.nih.gov/42120723/ Conteúdo informativo e educacional. A ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
... Orforglipron — an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) Clinical note: Orforglipron is now FDA ...
doi:10.1056/NEJMoa2511774. Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511-519. doi ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. More about Foundayo (orforglipron). Check interactions ...
... 10.1056/NEJMoa2500969 10.1056/NEJMoa2511774 10.1056/NEJMoa2032183 10.1056/NEJMoa2501006 10.1002/cpt.70377 10.1007/s40262-021-01025-x · May be ...
doi: 10.1056/NEJMoa2511774. 4. Wise J. New weight loss pill outperforms oral semaglutide for diabetes patients, study reports. BMJ 2026;392 ...
doi:10.1056/NEJMoa2511774. Food and Drug Administration. Saxenda label. Novo Nordisk. Novo Nordisk receives FDA approval for Wegovy to treat ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393:1796–1806. doi: 10.1056/NEJMoa2511774 ...
doi: 10.1056/NEJMoa2511774 Michalak W, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect ...
doi: 10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 ...
... 10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025. doi ...
... 10.1056/NEJMoa2511774; Wharton S, et al. N Engl J Med. 2025. doi:10.1056/NEJMoa2500969.; US Food and Drug Administration prescribing ...
... 10.1056/NEJMoa2511774; Wharton S, et al. N Engl J Med. 2025. doi:10.1056/NEJMoa2500969.; US Food and Drug Administration prescribing ...
doi: 10.1056/NEJMoa2511774; Foundayo [prescribing information]. 4/2026. Eli Lilly & Co. Indianapolis, IN. Accessed April 8, 2026 at https ...
https://doi.org/10.1056/NEJMoa2511774; Zepbound [package insert]. Eli Lilly and Company. Updated February 2026. Accessed on April 13, 2026 at ...
https://doi.org/10.1056/NEJMoa2511774; Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M ...
... 10.1056/NEJMoa2511774. 3. A research study to see how semaglutide helps people with excess weight, lose weight (STEP UP) (STEP UP) ...
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
... 10.1056/NEJMoa2511774 - Horn DB, Ryan DH, et al. Orforglipron in obesity with type 2 diabetes (ATTAIN-2). Lancet. 2025. DOI: 10.1016/S0140 ...
7. Horn, D.B. ... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes ...
doi:10.1056/nejmoa2511774. 19. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). Clinical Trials ...
doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PMID: 40960239. View all 9 comments · tatitafernandez. Mi querido doctor ! Siempre estudiando ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796–1806 (2025). Article PubMed ...
... 10.1056/nejmoa2511774. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients ...
... 10.1056/nejmoa2511774. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients ...
... 10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] doi ...
... 10.1056/NEJMoa2511774. 2. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide ...
... 10.1056/NEJMoa2511774. 6. Horn DB, Ryan DH, Kis SG, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
... está disponível para comercialização no Brasil. DOI: 10.1056/NEJMoa2511774 Dr. Filippo Pedrinola CRM 62253-SP | RQE 26961".
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://pubmed.ncbi ...
S Wharton et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med 2025; 393:1796. doi:10.1056 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-806. 4. Horn DB, et al ...
doi:10.1056/NEJMoa2511774. [Study 750] Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with ...
... 10.1056/NEJMoa2032183. Lincoff AM, Brown-Frandsen K, Colhoun HM, et ... NEJMoa2511774. FDA approves first new molecular entity under ...
doi:10.1056/NEJMoa2511774. Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #controldepeso ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
; et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): ...
New England Journal of Medicine, Article NEJMoa2511774. https://doi.org/10.1056/NEJMoa2511774; Horn, D. B., Ryan, D. H., Giljanovic Kis, S ...
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med ...
doi: 10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025.
OCR: Weight Loss & Nutrition Orforglipron, an Oral Small- Molecule GLP-1 Receptor Agonist for Obesity Treatment IG @SueRay328 Threads ...
The main content is about "Weight Loss & Nutrition" focusing on "Orforglipron, an Oral Small-Molecule GLP -1 Receptor Agonist for Obesity ...
... 10.1056/NEJMoa2511774 Mounjaro SURMOUNT-1 Trial (NEJM, 2022): https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 #foundayo #mounjaro #glp1 ...
doi:10.1056/NEJMoa2511774; Bays HE, Burridge K, Richards J, Fitch A. Obesity Pillars roundtable: Excessive weight reduction with highly ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. More about orforglipron. Check interactions · Compare ...
https://doi.org/10.1056/NEJMoa2511774. 10. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity ...
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” https://www.nejm.org/doi/abs/10.1056/NEJMoa2511774.
“Orforglipron for Obesity.” New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2511774. Results from the Phase 3 ATTAIN-1 trial in adults ...
DOI: 10.1056/NEJMoa2511774. Dr. Filippo Pedrinola CRM 62253-SP | RQE 26961. View all 9 comments · andrezawurzba. A ajuda extrínseca é ...
doi: 10.1056/NEJMoa2511774; Reuters. Lilly's weight-loss pill wins U.S. approval. Published April 1, 2026. Accessed April 9, 2026. https ...
doi: 10.1056/NEJMoa2511774; Foundayo [prescribing information]. 4/2026. Eli Lilly & Co. Indianapolis, IN. Accessed April 10, 2026 at https ...
https://doi.org/10.1056/NEJMoa2511774. Read next. Foundayo vs Wegovy: How do they compare for weight loss? Comparing Foundayo vs. oral Wegovy ...
doi: 10.1056/NEJMoa2511774; FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of ...
doi:10.1056/NEJMoa2511774. Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #controldepeso # ...
But many more have trouble affording the costly shots. Study details. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ...
... 10.1056/NEJMoa2511774 ATTAIN-2 Trial — Orforglipron in obesity with type 2 diabetes: https://doi.org/10.1016/S0140-6736(25)02165-8 #foundayo ...
doi:10.1056/NEJMoa2511774. Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #controldepeso ...
... 10.1056/NEJMoa2511774 · Sloop KW, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774. #Orforglipron #Glp1 #Obesidad #Nutricionclinica #nutriologa.
... 10.1056/NEJMoa2511774 https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1 ...
DOI: 10.1056/NEJMoa2511774 · FDA approval: Foundayo (orforglipron), 1º abr/2026. #orforglipron #foundayo #glp1 #diabetes · View all 3 comments.
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. PMID ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056 ...
... 10.1056/NEJMoa2511774. 6. Horn DB, Ryan DH, Kis SG, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056 ...
The FDA approved orforglipron, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and overweight with weight ...
2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PMID: 40960239. Like.
... 10.1056/NEJMoa2511774. 4. Rosenstock J, Yabe D, Cox D, et al; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron ...
org/doi/full/10.1056/NEJMoa2511774 But what about diet & Exercise? The look AHEAD Study (PMID: 25707379) observed an average of 7.9 ± 0.3 kg ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. May be an image of text · ? · ?. Yicai ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. | Facebook. Log in. Facebook. No photo ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. May be an image of text · ? · ?. Yicai ...
... orforglipron, an oral small-molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. No photo description available. Like ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
N Engl J Med 2025;393:1796-1806 - https://www. nejm.org/doi/full/10.1056/NEJMoa2511774 N Engl J Med 2023;389:877-888 - https ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;NEJMoa2511774. Wharton S, Rosenstock J ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. Available from ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. September 16, 2025 ...
doi:10.1056/NEJMoa2511774 · Horn DB, et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N. Engl. J. Med. 2025,393, 1796–1806. [CrossRef]. 47 ...
org/doi/full/10.1056/NEJMoa2500969 2. https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 3. https://www.accessdata.fda. gov ...
... 10.1056/NEJMoa2511774. Newsletter. Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1 upvote · 2 comments. [Article] Summation and ...
org/doi/full/10.1056/NEJMoa2500969 2. https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 3. https://www.accessdata.fda. gov ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
... Sean Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM 2025.
org/doi/full/10.1056/NEJMoa2511774#:~: text=Conclusions, other%20GLP%2D1%20receptor%20agonists. #obesite #maigrir #pilulemiracle #wegovy #mounjaro #saxenda ...
Source: https://www.nejm. org/doi/full/10.1056/NEJMoa2511774#:~: text=Conclusions, other%20GLP%2D1%20receptor%20agonists. #obesite #maigrir #pilulemiracle ...
Source: https://www.nejm. org/doi/full/10.1056/NEJMoa2511774#:~: text=Conclusions, other%20GLP%2D1%20receptor%20agonists. #obesite #maigrir #pilulemiracle ...
org/doi/full/10.1056/NEJMoa2511774?query=feature d_home · May be a graphic of text.
https://www.nejm. org/doi/full/10.1056/NEJMoa2511774?query=feature d_home · May be a graphic of text. Selina Diaz and Steve Condiotti ·
N Engl J Med 2025;393:1796-806. DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2511774?query=featured_home. more. September 16 · _popo_solo's profile picture · _popo_solo. •.
org/10.1056/NEJMoa2511774. 추천 콘텐츠 더 보기. 옆으로 자는 사람은 어깨가 아프다. 이 요령을 아는 사람은 거의. Derila. 옆으로 자는 사람은 어깨가 아프다. 이 요령 ...
... N Engl J Med 2025;393:1796-1806 DOI: 10.1056/NEJMoa2511774. Susan Pacheco Telma and 43 others ·
Aquí te dejamos el artículo. Jastreboff AM et al. Orforglipron for the Treatment of Obesity without Diabetes. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774 # ...
treat population. DOI: 10.1056/NEJMoa2511774. Copyright © 2025 Massachusetts Medical Society. RESULTS A total of 3127 patients underwent randomization. The ...
... 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos. Log in.
DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos · Puede ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [article]Dynamic control of Na-Cl ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [Article]The impact of cannabis and ...
... 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes - ATTAIN-2) ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
2025;393(18):1796-1806. 15. Krüger N, Schneeweiss S, Fuse K, et al. maintenance of body weight reduction in doi:10.1056/NEJMoa2511774
N Engl J Med 2025;393:1796-806. DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes ...
New England Journal of Medicine, Article NEJMoa2511774. https://doi.org/10.1056/NEJMoa2511774; Horn, D. B., Ryan, D. H., Giljanovic Kis, S ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM 2025. An oral GLP-1 shows clinically meaningful ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for ...
doi:10.1056/NEJMoa2511774. Garvey WT, Blüher M, Contreras CKO, et al. Coadministered cagrilintide and semaglutide in adults with overweight ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase ...
... 10.1056/NEJMoa2511774 Published on September 16, 2025 Patients GLP-1 receptor agonist •3127 adults •Mean age, 45 years •Women: 64%; Men: 36 ...
... New England journal of medicine, 393(18), 1796–1806. https://doi. org/10.1056/NEJMoa2511774. Tiến Lê and 3 others ·
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment In patients with #obesity, incretin-based therapies such ...
Published in NEJM (2025): DOI 10.1056/NEJMoa2511774 #ObesityCare #GLP1 #Orforglipron #NEJM #PharmaInnovation #WeightLoss #MetabolicHealth ...
... 10.1056/NEJMoa2511774| Published September 16, 2025 Patients GLP-1 receptor agonist 3127 adults •Mean age, 45 years •Women: 64%; Men: 36 ...
... 1806. https://doi.org/10.1056/NEJMoa2511774 #womeninscience #scienceculture #stemcommunity #womeninstem #sciencelove".
Published in NEJM (2025): DOI 10.1056/NEJMoa2511774 #ObesityCare #GLP1 #Orforglipron #NEJM #PharmaInnovation #WeightLoss #MetabolicHealth ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [Article] Glucagon-Like Peptide-1 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Published in NEJM (2025): DOI 10.1056/NEJMoa2511774 #ObesityCare #GLP1 #Orforglipron #NEJM #PharmaInnovation #WeightLoss #MetabolicHealth ...
... 10.1056/NEJMoa2511774 Published on September 16, 2025 Patients GLP-1 receptor agonist •3127 adults •Mean age, 45 years ·Women: 64%; Men: 36 ...
... 10.1056/NEJMoa2511774 Published on September 16, 2025 Patients GLP-1 receptor agonist •3127 adults •Mean age, 45 years ·Women: 64%; Men: 36 ...
... 10.1056/NEJMoa2511774 | Facebook. Join. Facebook. May be a graphic of ... org/doi/full/10.1056/NEJMoa2511774. كوثر عماد and 5 others ·
Published in NEJM (2025): DOI 10.1056/NEJMoa2511774 #ObesityCare #GLP1 #Orforglipron #NEJM #PharmaInnovation #WeightLoss #MetabolicHealth ...
... 10.1056/NEJMoa2511774. Log in ·
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" (https://www.nejm.org/doi/full/10.1056/NEJMoa2511774) ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity November 5, 2025. DOI: 10.1056/NEJMdo008238
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Close menu. #more to come #obesity · Orforglipron, an Oral ...
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · HC Shih and 191 others ·
Published in NEJM (2025): DOI 10.1056/NEJMoa2511774 #ObesityCare #GLP1 #Orforglipron #NEJM #PharmaInnovation #WeightLoss #MetabolicHealth ...
[Article] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 1. 2. [ARTICLE] AJM300 (carotegrast methyl), an ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment – NEJM 4. Dementia Risk in People With Type 1 Diabetes and ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
... injection. 11% while I think the injection is closer to 15%. https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 · Lucky_Army_5324. • 14d ago.
... 10.1056/NEJMra2403308 #GastroAcademia #NEJM #FibrosisHepática #MASH ... NEJM 2025; DOI: 10.1056/NEJMoa2511774. more. October 15.
https://www.nejm.org/doi/full/10.1056/NEJMoa2511774. I got my previous comment deleted because the link wasn't great I guess? So 2nd attempt ...
DOI: 10.1056/NEJMoa2511774. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774. अपवोट करें 1 डाउनवोट करें 2 ...
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
DOI: 10.1056/NEJMoa2511774 URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774.
... 10.1056/NEJMoa2511774. Knop, Filip K et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
... metodosaudavel #avaliacaointegrativa #estilodevida #sematalhos Fonte: https://www.nejm.org/doi/10.1056/NEJMoa2511774".
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · 丁噹and 130 others ·
New England Journal of Medicine, NEJMoa2511774. https://doi.org/10.1056/NEJMoa2511774; BioSpace. Pfizer ends oral GLP-1 candidate danuglipron ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774. ¿Crees que ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · Yuhyea Chen and 69 others ·
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
The New England Journal of Medicine. Published online September 16, 2025. doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text · 이강휴 and 32 others ·
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text · 이강휴 and 32 others ·
... 10.1056/NEJMoa2511774. Join ·
... 10.1056/NEJMoa2511774. more. View all 310 comments. 1 day ago · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
doi:10.1056/nejmoa2511774. 8. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 ...
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text · Joonyub Lee and 11 others ·
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text · Taegee Min and 17 others ·
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text. Tae-Yong Choi and 16 others ·
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Wharton S, Aronne LJ, Stefanski A, et al. The New England ...
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · Hung-Wei Cheng and 88 others ·
New Results from ATTAIN-1 ➝ An Oral Small Molecule GLP-1 Receptor Agonist for Obesity Treatment. Learn more: https://e.lilly/3KoWT4C.
... 10.1056/NEJMoa2511774) publiziert. Der Hersteller hofft auf eine Zulassung im nächsten Jahr. rme. Zum Weiterlesen anmelden. Liebe Leserinnen ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... 10.1056/NEJMoa2511774 Cite This Page: MLA APA Chicago European Association for the Study of Diabetes. "Scientists reveal pill that helps ...
N Engl J Med 2025;393:1796-806. DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes ...
Kaynak: https://www.nejm. org/doi/pdf/10.1056/NEJMoa2511774 Semaglutid (Ozempic, Wegovy) veya tirzepatid (Mounjaro, Zepbound) gibi ilaçlar ...
Wharton et al., NEJM, 2025.DOI : 10.1056/NEJMoa2511774 (3) S. Wharton et al., NEJM, 2025;393:1077-87 (4) J. Rosenstock et al., The Lancet ...
... Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (Sept 16, 2025) This is an extraordinary achievement for ...
org/doi/10.1056/NEJMoa2511774 Science often moves faster than ethics. Should it? Comment below, like this post, and follow our page. nejm.org.
Två nya studier har sett på effekten av av orala GLP1-analogerna semaglutid och orforglipron.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
doi:10.1056/NEJMoa2511774. Orforglipron, a small-molecule, nonpeptide oral GLP-1 receptor agonist, at multiple doses produced significant ...
New England Journal of Medicine, 2025; DOI: 10.1056/NEJMoa2511774. Cite This Page: MLA; APA; Chicago. European Association for the Study of ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 #glp1 #orforglipron #oral #dieting #weightloss. more. 2 days ago · drhowardsmithreports's ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
... 10.1056/NEJMoa2511774. Centro Científico de Medios Alemania (2025). Pastilla para adelgazar en lugar de inyección: Eli Lilly publica los ...
... 10.1056/NEJMoa2511774#:~:text=Conclusions,other%20GLP%2D1%20receptor%20agonists. #obesite #maigrir #pilulemiracle #wegovy #mounjaro #saxenda ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
The NEJM just reported impressive weight loss with Orforglipron, the first oral small-molecule GLP-1 receptor agonist. No more injections !
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. https://pubmed.ncbi.nlm.nih.gov/40960239/. (2025 ...
... 10.1056/NEJMoa2511774 Semaglutid (Ozempic, Wegovy) veya tirzepatid (Mounjaro, Zepbound) gibi ilaçlar peptid yapıda oldukları için ağızdan ...
... 10.1056/NEJMoa2511774. more. 21 hours ago · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy · Consumer Health Privacy.
https://doi.org/10.1056/NEJMoa2511774. Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. do, Jacob, S., Karlsson, T., Shaji, C., Rubino, D ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine . DOI: 10.1056/NEJMoa2511774.
N Engl J Med, DOI: 10.1056/NEJMoa2511774. 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点 ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
38 likes, 0 comments - shideh_amirifeli on September 17, 2025: "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity ...
doi:10.1056/NEJMoa2511774. Newsletter. Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
DOI: 10.1056/nejmoa2511774. Journal information: New England Journal of Medicine. Key medical concepts. orforglipronObesity. Clinical categories.
org/doi/full/10.1056/NEJMoa2511774. May be an image of 1 person and text. May be an illustration of 1 person and text that says '16:30-. May be ...
Phase 3 trial just published in NEJM for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an ...
... 10.1056/NEJMoa2511774. Log in ·
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 DOI: 10.1056/NEJMoa2511774.
org/doi/full/10.1056/NEJMoa2511774 · May be an image of 1 person and text · May be an illustration of 1 person and text that says '16:30- · May ...
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 DOI: 10.1056/NEJMoa2511774.
doi.org/10.1056/NEJMoa2511774. Be the first to rate this article. Posted in: Medical Research News | Medical Condition News | Healthcare News.
... -1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025 Sep 16. DOI: 10.1056/NEJMoa2511774.".
... 10.1056/NEJMoa2511774. Log in ·
N Engl J Med. 2025;doi:10.1056/NEJMoa2511774. Perspective. Back to Top. Ken Fujioka, MD.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Article Publication Date. 16-Sep-2025. COI Statement. See ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
... treatment" N Engl J Med 2025; DOI: 10.1056/NEJMoa2511774. Comment. Please enable JavaScript to view the comments powered by Disqus.
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 DOI: 10.1056/NEJMoa2511774.
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 DOI: 10.1056/NEJMoa2511774.
org/doi/pdf/10.1056/NEJMoa2511774. May be an image of text that says 'ENGLAND 80M1of11 MEDICINE ARTICLE Sean Wharton,. May be a graphic of ...
अपवोट करें 1 डाउनवोट करें 2 टिप्पणियों पर जाएँ शेयर करें. कमेंट सेक्शन. u/Hot_Store2689 अवतार · Hot_Store2689. • 23 दिन पहले. Profile Badge for the Achievement Top ...
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 DOI: 10.1056/NEJMoa2511774.
Additionally, metabolic factors including diabetes, chronic kidney disease, obesity, and metabolic syndrome predispose to enthesis pathology ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... see with injectables? https://www.nejm.org/doi/full/10.1056/NEJMoa2511774?query=featured_home. more. 21 hours ago · michaelalbertmd. •. Follow.
A target trial emulation study on impact of GLP-1RAs on cardiovascular and kidney outcomes using TriNetX data suggested reduced risks in ...
The #obesity treatment landscape is evolving, with GLP-1s, dual agonists, and new oral therapies. Download our guide for strategies to boost ...
... 10.1056/NEJMoa2407001) ... https://www.nejm.org/doi/full/10.1056/NEJMoa2500969, https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
Orforglipron, an Oral Small-Molecule GLP-1 Receptor ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos · Puede ...
[749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [ ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos. Puede ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos · Puede ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · 朱朱and 84 others ·
doi: 10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be an image of text · Ki-Hyun Jeon and 25 others ·
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
Orforglipron approved by FDA for obesity management Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity Treatment Sean ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... 10.1056/NEJMoa2505669), el estudio ACHIEVE-1 evaluó su eficacia y ... 2025; DOI: 10.1056/NEJMoa2511774 #EducarParaCambiar #IMENAO ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
NEJM, 2025: [DOI: 10.1056/NEJMoa2505669] (Eficácia em Obesidade - ATTAIN-1). 3. NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados em Diabetes ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
New England Journal of Medicine, 2025; DOI: 10.1056/NEJMoa2511774 Cite This Page: MLA APA Chicago European Association for the Study of Diabetes ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056 ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
... www.nejm.org/doi/full/10.1056/NEJMoa2511774. more. View all 137 comments. 11 hours ago · bia_europe's profile picture. bia_europe. •. Follow.
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
doi:10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 ...
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · JoeJoe Ho and 81 others ·
N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · 林建良and 153 others ·
doi:10.1056/NEJMoa2511774. S. Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England ...
NEJM 2024/2025.(DOI:10.1056/NEJMoa2404881-Referência real baseada na publicação de 2024). ... NEJM, 2025: [DOI: 10.1056/NEJMoa2511774] (Resultados ...
... treatment. N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · 陳逸燕and 82 others ·
N Engl J Med. 2025;393:1796‑1806. DOI:10.1056/NEJMoa2511774 · Yuchen Huang and 163 others ·
... www.nejm.org/doi/full/10.1056/NEJMoa2511774. more. View all 184 comments. 19 hours ago · bia_europe's profile picture · bia_europe. •. Follow.
N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774 #EducarParaCambiar #IMENAO #EducaciónIMENAO. more. 2 days ago · imenao.educacion. •. Follow.
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025.
) Refernce : https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be a graphic of text. Ammar Mohammed Sulaiman and 2 others ·
... 10.1056/NEJMoa2511774?query=featured_home. more. September 16 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
org/doi/full/10.1056/NEJMoa2511774. May be an image of 1 person and text. May be an illustration of 1 person and text that says '16:30-. May be ...
... www.nejm.org/doi/full/10.1056/NEJMoa2511774. more. View all 184 comments. 23 hours ago · bia_europe's profile picture. bia_europe. •. Follow.
... of Obesity without Diabetes. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774 #EducarParaCambiar #IMENAO #EducaciónIMENAO ·
doi:10.1056/NEJMoa2511774. #Orforglipron #Glp1 #Obesidad #Nutricionclinica #nutriologa · 1 hour ago · promedica_sport_'s profile picture ...
) Refernce : https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be a graphic of text · Ammar Mohammed Sulaiman and 2 others ·
... www.nejm.org/doi/full/10.1056/NEJMoa2511774. more. View all 37 comments. 1 hour ago · bia_europe's profile picture · bia_europe. •. Follow.
DOI: 10.1056/NEJMoa2511774 • Horn DB, et al. ATTAIN‑2. The Lancet, 2025. DOI: 10.1016/S0140-6736(25)02165-8 • Rosenstock J, et al. ACHIEVE‑1 ...
) Refernce : https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be a graphic of text · صهيب الراوي and Ali Salim ·
DOI: 10.1056/NEJMoa2511774 . . #sobrepeso #obesidad #endocrinologia #pokeendocrino #MedicinaInterna #Residentes #medicina #semestrosos. Puede ...
... Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025, 393:1796-806. 10.1056/NEJMoa2511774 ...
doi:10.1056/NEJMoa2511774. #Orforglipron #Glp1 #Obesidad #Nutricionclinica #nutriologa · September 24 · promedica_sport_'s profile picture ...
) Refernce : https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · Kan være en grafik af tekst. صهيب الراوي og Ali Salim ·
) Refernce : https://www.nejm. org/doi/full/10.1056/NEJMoa2511774 · May be a graphic of text. صهيب الراوي and Ali Salim ·
org/10.1056/NEJMoa2511774 2. Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2026). Orforglipron for maintenance of body weight ...
Read the study: “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, 2025 ...
org/doi/full/10.1056/NEJMoa2511774. May be an image of 1 person and text. May be an illustration of 1 person and text that says '16:30-. May be ...
M
ET
N
TL
AM
YM
PD
BM
太
HR
医ブ
DA
F
SC
AR
FC
AT
PO
LP
GL
자원
D
Y第
LL
Tで
B
UF
A
A
EG
BM
UR
LP
ボ
旅T
AH
DB
NP
DJ
L
A
ER
DM
AM
LC
JM
DK
IP
NH
S
AM
AW
S
KD
O
BF
Z
DC
A
GD
DD
DD
VB
FH
MM
JY
A
CP
E
TR
MP
IT
JC
DD
DA
NF
AR
JP
MH
DM
TR
JC
IL
TE
Sシ
SG
KW
DD
A
J
DH
SR
AF
DR
KA
D
IN
MT
JM
JR
SX
PF
MR
SP
DB
DG
WM
GP
DA
N
PM
DS
GM
S
AC
HI
弓Y
医
BA
EC
S
MT
JA
RG
JQ
HE
DS
SB
AG
DG
J
DS
A
RL
CT
CM
AV
AM
W
RM
AG
BV
M
V
RC
J
FL
NA
S
RP
MR
ES
UD
PB
DD
VM
LP
AL
AL
P
L
MS
Z
DJ
J
U
M
FT
土
LU
さ元
BO
GG
サ
JC
MH
TT
TM
D
FS
GS
DK
MA
KN
SN
JP
NS
TT
RK
SH
M
DR
HF
SH
DC
AG
あ便
AO
A
JA
PL
MA
JN
MH
B
やア
MY
MM
C
JA
AV
JC
S
GF
SA
DE
ER
AE
NF
DF
JF
SB
DE
ME
MK
DD
RR